WHO ICTRP trial
A clinical study for the efficacy and safety of artemisinin-pipequine tablets in…
ChiCTR2000033049 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000033049 |
|---|---|
| Public title | A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients |
| Scientific title | A clinical study for the efficacy and safety of artemisinin-pipequine tablets in the treatment of the untreated mild or common type novel coronavirus pneumonia (COVID-19) patients |
| Primary sponsor | Hongqi Hospital Affiliated to Mudangjiang Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Novel Coronavirus Pneumonia (COVID-19) |
| Interventions | Case series:Taking artemisinin-pipequine tablets |
| Registration date | May 18, 2020 |
| Target size | Case series:160 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: